BeOne Medicines Ltd. (ONC) is a publicly traded company in the Healthcare sector, operating within the Medical - Pharmaceuticals industry. The current CEO is John V. Oyler.
ONC has IPO date of 2016-02-02, 11,000 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $33.13B.
BeOne Medicines is a global oncology company dedicated to discovering, developing, and commercializing innovative cancer therapies. Originally founded as BeiGene in 2010, the company rebranded to BeOne in late 2024 and relocated its headquarters to Basel, Switzerland in 2025, now operating across over 45 countries. The company has established market leadership in immuno-oncology and targeted therapies, with flagship products including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications worldwide, and Brukinsa (zanubrutinib), a BTK inhibitor that generates over $1.3 billion in annual sales across the U.S., Europe, and China. BeOne's strategy combines internal research and development with externally sourced assets to build a robust pipeline targeting hematologic malignancies and solid tumors.
